Home Newsfeeds Truist Securities Maintains Buy on Sutro Biopharma, Lowers Price Target to $21

Truist Securities Maintains Buy on Sutro Biopharma, Lowers Price Target to $21

Truist Securities analyst Asthika Goonewardene maintains Sutro Biopharma (NASDAQ:STRO) with a Buy and lowers the price target from $37 to $21.

byBenzinga Newsdesk

August 23, 2022

1 minute read

Truist Securities analyst Asthika Goonewardene maintains Sutro Biopharma (NASDAQ:STRO) with a Buy and lowers the price target from $37 to $21.

Analyst Ratings

What 9 Analyst Ratings Have To Say About Murphy Oil

By Benzinga Insights

November 23, 2:04 PM

Over the past 3 months, 9 analysts have published their opinion on Murphy Oil (NYSE:MUR) stock. These analysts…

MUR

General Motors’ Manufacturing Momentum May Be Pressured On UAW Demands: Report

By Nabaparna Bhattacharya

September 6, 9:08 AM

General Motors Company (NYSE: GM) reportedly said that the United Auto Workers union's demands will pressure the auto behemoth's manufacturing momentum.

News

‘Microsoft Executive Emails Hacked By Russian Intelligence Group, Company Says A Group Called Nobelium Carried Out The Attack, Which It Detected Last Week’ – CNBC

By Benzinga Newsdesk

January 19, 6:00 PM

https://www.cnbc.com/2024/01/19/microsoft-executive-emails-hacked-by-russian-intelligence-group-company-says.htmlMicrosoft said in a Friday regulatory filing that a Russian hacking group accessed some of the software

MSFT